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Abstract 
Iron detoxification of human blood plasma was studied with resins containing desferrioxamine B (DFO) or 
3-hydroxy-2-methyl-4(1H)-pyridinone (HMP) as iron(III)-chelating groups. The behaviour of four resins was investi- 
gated: DFO-Sepharose, HMP-Sepharose and crosslinked copolymers of 1-(/3-acrylamidoethyl)-3-hydroxy-2-methyl- 
4(lH)-pyridinone (AHMP) with 2-hydroxyethyl methacrylate (HEMA) and of AHMP with N,N-dimethylacrylamidc 
(DMAA). The efficiency of iron detoxification of plasma of the resins was mainly dependent on the affinity of the 
ligands and the hydrophilicity of the resins. The results of a stability study in phosphate-buffered saline at a 
physiological pH indicated that AHMP-DMAA was the most stable resin, whereas the Sepharose gels had a 
relatively lower stability. Experiments with the AHMP-DMAA resin showed that the resin was able to remove iron 
from plasma with different iron contents, and from plasma poisoned with FeCl 3, iron(III) citrate or transferrin. A
rapid removal from free serum iron was observed, whereas iron from transferrin was removed slowly afterwards. 
Only the overload iron was removed since in all cases the normal serum iron level of ca. 1 ppm was obtained. 
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I. Introduction 
Iron overload leads to toxic effects be- 
cause the human body has no physiological 
route for the elimination of excess iron [1,2]. 
In the therapy of iron overload, excess iron 
must be removed by chelators. The current 
clinical drug for iron overload is desferriox- 
amine B (DFO), a naturally occurring iron 
i Presented at the International Meeting on Macromolecular 
Metal Complexes (MMC V), Bremen, 1993. 
* Corresponding author. 
chelator which is administered intravenously. 
DFO reduces iron levels by forming a stable, 
soluble complex with iron(III), which is elim- 
inated in urine and stool [3,4]. 
Although DFO therapy is effective in re- 
moving large quantities of iron rapidly, there 
are several drawbacks in its use. DFO is not 
an orally active drug, and has a short plasma 
residence time [5,6]. Furthermore, the drug 
and its iron complex are toxic when present 
in large amounts [7], and the dose of DFO 
which can be administered intravenously is
also limited by its adverse effects on blood 
pressure [8]. 
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In order to minimize DFO toxicity while 
maintaining its effectiveness, DFO was bound 
to polymers. These DFO-bound polymers 
had a lower toxicity than free DFO, whereas 
a similar effectiveness as DFO was observed 
[9,10]. In addition, DFO-containing resins 
and a device with immobilized DFO were 
developed for the extracorporeal removal of 
iron. However, the effectiveness of the im- 
mobilized DFO was low, and it seemed im- 
possible to reduce the serum iron concentra- 
tion to the normal level [11-13]. 
Iron(Ill) chelation by chelators other than 
DFO has also been studied [4,14-16]. It was 
found that 3-hydroxy-2-methyl-4(1H)-pyr- 
idinone (HMP) derivatives are strong 
iron(III) chelators and have a higher affinity 
towards iron(III) (log/33 = 36) [17] than DFO 
(log/3 -= 31) [18]. Water-soluble HMP deriva- 
tives are orally active and uncharged under 
physiological conditions both as the free li- 
gands and as the iron complexes, and are 
relatively selective for iron(Ill) under in vivo 
conditions [19,20]. 1,2-Dimethyl-3-hydroxy- 
4(1H)-pyridinone was extensively studied in 
iron-overloaded animal models and in thalas- 
saemia patients, and removed iron relatively 
efficiently at high dose [21,22]. However, the 
dose required to keep a previously well 
chelated patient in negative iron balance ap- 
peared to be unacceptably high. At a dose of 
100 mg/kg,  peak levels of iron-free drug 
exceeded 100 mM, significantly within the 
concentration range known to inhibit ribonu- 
cleotide reductase [14]. 
We recently reported on the synthesis and 
properties of new iron(Ill) chelators with 
immobilized DFO groups or HMP groups 
[23-27]. Because it was reported that with 
soluble HMP chelators high doses had to be 
used for iron removal [21,22], it seemed 
worthwile to study the applicability of 
iron(III)-chelating systems with immobilized 
HMP chelators in more detail. 
In this paper, we report on the application 
of iron(III)-chelating resins with immobilized 
DFO or HMP groups for iron detoxification 
of human blood plasma. Their stability in 
phosphate-buffered saline (PBS, pH 7.4) and 
iron detoxification ability were compared. 
Results are also given on the iron removal 
from plasma with various iron levels and 
from plasma poisoned with FeCI3, iron(III) 
citrate or transferrin, as well as the iron 
detoxification rate. 
2. Experimental 
2.1. Materials 
Human blood plasma containing 21.7 m M 
citrate for anticoagulation (ACD plasma) was 
provided by the Blood Bank (Enschede, 
Netherlands). FeCI3 .6H20 , iron(III) citrate 
and human apotransferrin (containing only 
4.9 ppm of iron) were obtained from Merck, 
Janssen and Sigma, respectively, and used as 
received. 
2.2. Preparation of iron (III)-chelating resins 
DFO-Sepharose gel and HMP-Seph-  
arose gel were synthesized as described pre- 
viously [23,24], with ligand densities of 20.8 
and 18.3 /zmol/ml, respectively. AHMP-  
HEMA and AHMP-DMAA resins were de- 
rived from copolymerization of 1-(/3-acryl- 
amidoethyl)-3-hydroxy-2-methyl-4(1H)-pyri- 
dinone (AHMP) with 2-hydroxyethyl metha- 
crylate (HEMA) or N,N-dimethylacrylamide 
(DMAA) in the presence of a crosslinking 
agent [25,26], and their ligand densities were 
214 and 460 ~mol /g ,  respectively. 
2.3. Stability study of the resins 
As an indication for the stability of the 
resins at physiological pH, the release of the 
ligands from the resins was determined in 
PBS (pH 7.4). The DFO-Sepharose and 
HMP-Sepharose gels were first washed with 
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distilled water. About 0.3 g of resin or 0.5 ml 
of gel was placed into 20 ml of PBS, and the 
mixture was rotated at 20°C. After a deter- 
mined time interval rotating was stopped for 
5-10 min, allowing the resin or gel to precip- 
itate. A part of the supernatant was removed 
for the determination f the concentration of
released ligands. The amount of DFO in the 
aqueous olution was determined by its maxi- 
mal absorbance in the range 195-210 nm, 
whereas the amount of HMP was deter- 
mined by its maximal absorbance at 280 nm 
with an ultraviolet-visible spectrophotome- 
ter. 
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Fig. 1. Structures of various iron(III)-chelating resins. 
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2.4. Iron detoxification 
Ferric trichloride and iron(III) citrate so- 
lutions were freshly prepared by adding ap- 
propriate amounts of FeC13.6H20 and 
iron(III) citrate in distilled water, respec- 
tively. Apotransferrin was saturated with 
iron(Ill) by dissolving apotransferrin i  the 
FeCI 3 solution, and incubated at 20°C for 4 
h. 
Plasma was poisoned by adding the 
above-mentioned iron(III)-containing solu- 
tions to various iron levels, and the plasma 
was rotated at 20°C for 1 h. DFO-Sepharose 
and HMP-Sepharose gels were washed with 
distilled water before use. 
Iron detoxification of plasma was carried 
out at 20°C by rotating the mixture of an 
iron-chelating resin and plasma. The rotating 
was stopped and the resin or gel was allowed 
to precipitate. The supernatant of the plasma 
was removed for the determination of the 
iron content with a Perkin-Elmer Zeeman 
5000 atomic absorption spectrophotometer 
(AAS). For comparison, a blank control was 
carried out and determined at the same con- 
ditions. 
3. Results and discussion 
Various iron(III)-chelating systems were 
investigated, and their structures are shown 
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Fig. 2. Stability of iron(liD-chelating resins in PBS (pH 7.4). 
28 
in Fig. 1. The stability of the iron(III)-chelat- 
ing resins at a physiological pH was studied 
(Fig. 2), and the results show that the 
Sepharose gels with immobilised ligands had 
a relatively lower stability probably due to 
hydrolysis of bonds between the ligands and 
the matrix, which is consistent with previous 
observations in distilled water [23,24]. It is 
noted that only small amounts of ligands 
were released from the AHMP-HEMA and 
AHMP-DMAA resins, which probably re- 
sulted from some unreacted monomers en- 
capsulated in the polymer networks. Because 
of the high stability of the resins in PBS and 
in water [25,26], a similar behaviour in plasma 
was expected. 
Table 1 
Iron detoxification of plasma a by various iron chelating resins b 
Iron chelating resin 
Code Amount Capacity (/xmol) 
Iron content in plasma c (ppm) 
Initial d Remaining 
Iron removal 
(%) 
DFO-Sepharose 0.5 ml 14.4 e 
HMP-Sepharose 1.0 ml 6.1 f 
AHMP-HEMA 75 mg 5.4 f 
AHMP-DMAA 40 mg 6.1 f 
4.26 1.57 63 
4.26 0.41 90 
4.26 3.86 9 
4.26 0.98 77 
a Poisoned by adding FeCI 3 solution to 5 ml of plasma. 
b Performed at 20°C for 24 h. 
c Mean value of three determinations. 
d After addition of FeCI 3. 
e (Amount of resin) x (ligand density). 
f (Amount of resin) × (ligand density) × 1/3. 
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Iron detoxification by various resins was 
studied with plasma poisoned with ferric 
chloride (Table 1). The resins were effective 
in iron removal from poisoned plasma, but 
differed in the efficiency. The HMP-Seph- 
arose gel had a higher efficiency than the 
DFO-Sepharose gel, which may be due to a 
higher affinity of the HMP ligands than DFO. 
Comparing the results between AHMP-  
HEMA, AHMP-DMAA and HMP-Seph- 
arose, it can be seen that the efficiency of 
AHMP-HEMA was much lower than that of 
AHMP-DMAA or HMP-Sepharose, which 
may be explained by their difference in 
iron(III)-chelating ability as observed previ- 
ously [25-27]. This difference in the ability 
between AHMP-HEMA and AHMP-  
DMAA or HMP-Sepharose is probably due 
to differences in the type of the polymeric 
matrices which may influence the hy- 
drophilicity or swelling extent, the diffusion 
rate of iron(III) into the resin and the steric 
hindrance of the ligands. In addition, AHMP 
and HEMA would not copolymerize well, 
which may have some bad effect on site 
distribution of AHMP and hence on the ac- 
cessibility of iron. 
Considering the stability as well as the 
efficiency, AHMP-DMAA had the most 
favourable properties, and for this reason 
more experiments were carried out with the 
AHMP-DMAA resin. 
The AHMP-DMAA resin was used in 
iron detoxification of plasma with various 
iron contents and the results are shown in 
Fig. 3. For unpoisoned plasma (iron content 
in this case was 0.86 ppm), only a small 
amount of iron was removed, while iron was 
removed at higher iron contents. It is inter- 
esting to note that by using different initial 
iron contents (0.86, 2.02, 4.26 and 6.52 ppm) 
the iron contents of the treated plasma were 
always in the region 0.6-1.2 ppm, the region 
of normal iron contents. 
It is known that the iron in plasma is 
tightly bound to its transport protein, trans- 
,3 
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Fig. 3. Iron detoxification of plasma with various iron con- 
tents. Experiments were carried out at 20°C for 24 h by 
rotating 40 mg of AHMP-DMAA resin and 5 ml of plasma 
with iron contents of 0.86 ppm (1, unpoisoned plasma), 2.02 
ppm (2), 4.26 ppm (3) and 6.52 ppm (4), respectively. The 
poisoned plasma was prepared by adding appropriate amounts 
of a FeCI 3 solution. 
ferrin. Normal serum iron levels fluctuate 
around 1 ppm, and typically only 30% of the 
iron binding sites of transferrin are occupied, 
making the total iron binding capacity (TIBC) 
ca .  3 ppm. From the results shown in Fig. 3 it 
can be seen that the iron contents of plasma 
after treatment with the AHMP-DMAA 
resin was lower than ca .  3 ppm, which indi- 
cates that the resin was able to remove iron 
from transferrin. 
The two major causes of iron overload are 
iron poisoning and /3-thalassemia [14]. Iron 
poisoning most often arises in small children 
through the inadvertent ingestion of iron 
preparations [14]. The only effective treat- 
ment of/3-thalassemia is to administer blood 
transfusion throughout life, which introduces 
large quantities of iron and transferrin [14]. 
In order to investigate the effect of the type 
of iron(III)-containing substance which poi- 
sons the plasma, iron detoxification by the 
AHMP-DMAA resin was studied with 
plasma to which was added FeC13, iron(III) 
citrate or transferrin (100% saturated with 
iron, Fe-binding form), respectively. 
In Fig. 4 the TIBC values and the iron 
contents of initial poisoned plasma as well as 
of treated plasma are given. For comparative 
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Fig. 4. Iron detoxification of plasma poisoned with FeCI3, 
iron(III) citrate or transferrin (100% iron saturated transfer- 
rin). Detoxification was performed with 40 mg of AHMP- 
DMAA resin and 5 ml of plasma at 20°C for 24 h. 
purposes the iron content of the initial poi- 
soned plasma in all three cases was brought 
to ca.  4 ppm. In the plasma poisoned with 
FeC13 and iron(III) citrate, the calculated 
TIBC based on the iron content of unpoi- 
soned plasma was 2.6 ppm, whereas the TIBC 
in the plasma poisoned with transferrin was 
7.7 ppm, which was calculated by taking into 
account he TIBC of unpoisoned plasma and 
the amount of transferrin added. It is obvi- 
ous that the resin was effective in iron re- 
moval from the poisoned plasma, and in all 
cases the iron content was reduced to ca.  1 
ppm, even with different TIBCs of the plasma 
and iron sources used. These results indicate 
that iron detoxification of plasma with the 
AHMP-DMAA resin was independent of 
the form of poisoning iron. In addition, it is 
important to note that only the overload iron 
was removed by the resin since in all cases 
the normal iron content in plasma of ca.  1 
ppm was obtained. 
Fig. 5 gives data on the rate of iron detoxi- 
fication of iron poisoned plasma by the 
AHMP-DMAA resin. It can be seen that 
removal of free iron (not bound by transfer- 
rin) was fast and complete within 1 h, result- 
ing in a serum iron concentration on the 
level of the TIBC. The iron from transferrin 
was removed slowly afterwards, and the iron 
concentration ultimately reached the normal 
iron level (in unpoisoned plasma). 
From the data shown in Table 1 it can be 
concluded that part of the iron from trans- 
ferrin could be removed by the DFO-Seph-  
arose gel. The remaining iron concentration 
(1.57 ppm) by using the gel was lower than 
that with DFO-immobil ized crosslinked 
polystyrene or polyacrolein observed by other 
workers [11,13] notwithstanding the different 
operation conditions. In their iron detoxifica- 
tion of plasma with a column process, only 
small amounts of iron could be removed 
from transferrin in poisoned plasma. They 
proposed that it was not possible to remove 
iron from transferrin because of the rela- 
tively low affinity of free DFO and the steric 
hindrance induced in the coupling of DFO 
[11,13]. The difference in behaviour of the 
DFO-polystyrene or the polyacrolein system 
and our DFO-Sepharose gel might be due 
to the high hydrophilicity of Sepharose gel 
and less steric hindrance between DFO and 
the matrix. It is noteworthy that using the 
AHMP-DMAA resin, the iron content in 
plasma could be reduced to 1 ppm, which 
showed a significant improvement in the iron 
detoxification of plasma compared with the 
reported results in a column process (the 
final iron content was 2-4 ppm) [11,13]. Al- 
though a difference in the iron removal by 
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28  
Fig. 5. Iron detoxification rate by the AHMP-DMAA resin. 
Experiments were performed at 20°C for 24 h by rotating 150 
mg of AHMP-DMAA resin and 25 ml of plasma poisoned 
with FeC13 solution. 
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using batch or column process may be pres- 
ent, the ability of the AHMP-DMAA resin 
in the iron removal is not supposed to change 
much when using it in a column process 
because the iron(III)-chelating capacity and 
ability of the AHMP-DMAA resin in a con- 
tinuous process with a column was found to 
be as high as in a batch process [26]. 
As shown, our iron-chelating resins, espe- 
cially the AHMP-DMAA resin, removed 
free serum iron completely and also part of 
the iron from transferrin, resulting in an iron 
concentration in the treated plasma of ca .  1 
ppm. The ability of the iron(III)-chelating 
resins to remove iron from plasma indicates 
the possibility of applying the resins in treat- 
ment of iron overload in blood, especially in 
extracorporeal detoxification of severe acute 
iron poisoning cases. 
4. Conclusions 
AHMP-HEMA and AHMP-DMAA 
resins, synthesized by copolymerization of 
AHMP with HEMA or DMAA in the pres- 
ence of a crosslinking agent, showed a higher 
stability in PBS than DFO- or HMP-im- 
mobilized Sepharose gels. 
All iron(III)-chelating resins were able to 
remove iron from poisoned plasma, and 
resins with a high hydrophilicity and with 
HMP ligands were more effective. 
By using the AHMP-DMAA resin, it was 
possible to reduce the iron contents of poi- 
soned plasma to ca .  1 ppm, the normal serum 
iron level in unpoisoned plasma. 
The iron(III) chelators, especially the 
AHMP-DMAA resin, had much better 
properties in iron detoxification than the 
DFO-immobilized resins reported previously. 
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